Characterization of metabolic landscape in hepatocellular carcinoma  

作　　者：Jing Wu Ran Xue Rong-Tao Jiang Qing-Hua Meng 

机构地区：[1]Department of Medical Oncology,Beijing You-An Hospital,Capital Medical University,Beijing 100069,China [2]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100036,China [3]National Laboratory of Pattern Recognition,Institute of Automation,Chinese Academy of Sciences,Beijing 100190,China

出　　处：《World Journal of Gastrointestinal Oncology》2021年第9期1144-1156,共13页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Supported by The Municipal Natural Science Foundation of Beijing,China,No.7192085;National Science and Technology Major Project of China,No.2018ZX10302206-003-007 and No.2017ZX10203202-001-005;The Capital Health Research and Development of Special,No.2018-1-3011;National Natural Science Foundation of China,No.81470877.

摘　　要：Hepatocellular carcinoma(HCC)is one of the most prevalent cancers worldwide,accounting for approximately 75%-85%of primary liver cancers.Metabolic alterations have been labeled as an emerging hallmark of tumors.Specially,the last decades have registered a significant improvement in our understanding of the role of metabolism in driving the carcinogenesis and progression of HCC.In this paper,we provide a review of recent studies that investigated the metabolic traits of HCC with a specific focus on three common metabolic alterations involving glycolysis,lipid metabolism,and glutamine addiction which have been gaining much attention in the field of HCC.Next,we describe some representative diagnostic markers or tools,and promising treatment agents that are proposed on the basis of the aforementioned metabolic alterations for HCC.Finally,we present some challenges and directions that may promisingly speed up the process of developing objective diagnostic markers and therapeutic options underlying HCC.Specifically,we recommend future investigations to carefully take into account the influence of heterogeneity,control for study-specific confounds,and invite the validation of existing biomarkers.

关 键 词：Hepatocellular carcinoma Metabolic reprogramming GLYCOLYSIS Lipid metabolism Glutamine addiction Diagnosis and treatment 

分 类 号：R735.7[医药卫生—肿瘤]